Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11267902 Crystalline antibody formulations

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Date Filed
November 6, 2018
Date of Patent
March 8, 2022
Patent Applicant
Amgen
Amgen
Patent Application Number
16182279
Patent Citations
‌
US Patent 10472424 Treatment with anti-PCSK9 antibodies
‌
US Patent 10472425 Stabilized formulations containing anti-PCSK9 antibodies
‌
US Patent 10494442 Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
‌
US Patent 10533045 Antibody purification and purity monitoring
‌
US Patent 10544232 Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
‌
US Patent 10611849 Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
‌
US Patent 10611850 Crystalline antibody formulations
‌
US Patent 10752701 Stabilized formulations containing anti-PCSK9 antibodies
‌
US Patent 10618971 Targeting rare human PCSK9 variants for cholesterol treatment
‌
US Patent 10077319 Anti-PCSK9-GLP-1 fusions and methods for use
•••
Patent Citations Received
‌
US Patent 11773184 Crystalline antibody formulations
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11267902
Patent Primary Examiner
‌
Nita M. Minnifield

Find more entities like US Patent 11267902 Crystalline antibody formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo